Danish cancer company IO Biotech is entering its third clinical collaboration with US-based pharmaceutical giant MSD. The ambition is to develop a drug for the treatment of three different types of cancer, it reports in a press release.
IO Biotech, which recently went public on the stock exchange in the US, wants to test its immune-modulating cancer therapy, IO102-IO103, in combination with MSD's multi-blockbuster drug Keytruda (pembrolizumab).
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.